Ernexa Therapeutics Inc. Operating Leases, Income Statement, Sublease Revenue
Ernexa Therapeutics Inc. (ERNA) reported Operating Leases, Income Statement, Sublease Revenue of $31.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-15.
Discontinued › Income Statement › Other Income
us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue · last filed 2016-03-15
- Ernexa Therapeutics Inc. operating leases, income statement, sublease revenue for fiscal 2014 was $31.00K, a 29.55% decline from fiscal 2013.
- Ernexa Therapeutics Inc. operating leases, income statement, sublease revenue for fiscal 2013 was $44.00K.
| Period end | Operating Leases, Income Statement, Sublease Revenue 12 month |
|---|---|
| 2014-12-31 | $31.00K 10-K · filed 2016-03-15 |
| 2013-12-31 | $44.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |